Pasithea Therapeutics Corp. (KTTA) stock
KTTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.51+0.08 (+17.64%)
Close on Nov 18, 2026Market cap $17.07MP/E –Yield –
Pasithea Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Pasithea Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.73M, up 54.0% year over year. For fiscal 2025 it was $7.98M, up 10.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.98M | +10.9% |
| FY2024 | Dec 31, 2024 | $7.20M | -11.1% |
| FY2023 | Dec 31, 2023 | $8.10M | +203.9% |
| FY2022 | Dec 31, 2022 | $2.67M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.69M | +71.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.94M | +70.1% |
| Q4 FY2025 | Dec 31, 2025 | $2.74M | +81.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.36M | -14.1% |
| Q2 FY2025 | Jun 30, 2025 | $2.15M | -8.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.73M | -1.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.51M | -54.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.58M | -2.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.36M | +16.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.75M | +59.6% |
| Q4 FY2023 | Dec 31, 2023 | $3.35M | +141.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.62M | +27.0% |
| Q2 FY2023 | Jun 30, 2023 | $2.03M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.10M | – |
| Q4 FY2022 | Dec 31, 2022 | $1.39M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.28M | – |
See a number that looks wrong?